Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | GL. Uy, J Godwin, MP Rettig, N Vey, M Foster, ML. Arellano, DA. Rizzieri, MS. Topp, G Huls, B Lowenberg, G Martinelli, S Paolini, F Ciceri, MG Carrabba, C Ballesteros-Merino, CB Bifulco, H Lelièvre, R La Motte-Mohs, D Li, J Sun, K Jacobs, K Spohn et. al. | ||||||||||||
Title | Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome | ||||||||||||
|
|||||||||||||
URL | http://www.bloodjournal.org/content/130/Suppl_1/637?sso-checked=true | ||||||||||||
Abstract Text | Blood 2017 130(Suppl 1):637 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Flotetuzumab | Flotetuzumab | 0 | 4 |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Flotetuzumab | MGD006|S80880 | Flotetuzumab (MGD006) is a humanized bispecific antibody that targets both CD123 and CD23, which may lead to anti-leukemic activity (Blood 2017 130(Suppl 1):637, PMID: 32493790, PMID: 32929488). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|